BIOTRONIK announces completion of enrollment in the iliac arm of the BIOFLEX-I Study

Published on:

BIOTRONIK, a leading manufacturer of cardiovascular technology, announced today that it has completed patient enrollment in the iliac arm of its BIOFLEX-I trial. Under the supervision of national primary investigator Dr. Mark W. Burket, Chief of the Cardiovascular Division at the University of Toledo Medical Center in Toledo OH, the trial will evaluate the safety and effectiveness of the Astron and Pulsar-18 stents in the treatment of peripheral vascular disease with a view towards gaining FDA approval.

The BIOFLEX-I trial is a prospective, non-randomized, multi-center IDE study consisting of two arms: SFA (superficial femoral artery) and iliac. Alongside ongoing enrollment in the SFA arm, the newly completed iliac arm evaluates the use of the Astron stent in the treatment of common or external iliac artery lesions. Astron is CE-marked and commercially available in over 50 countries worldwide. Astron stents were successfully implanted in 160 patients at 34 centers in the U.S. and Europe, completing enrollment in the iliac arm of the BIOFLEX-I trial.

“When treating disease in the iliac arteries, it’s important to have a variety of tools at your disposal,” commented Dr. Burket. “The Astron stent is an excellent option in the self-expanding category. Its flexibility, ease of deployment, and passive PROBIO coating make it a suitable choice for many patients.” 

“The completion of enrollment in the iliac arm of this study represents an important milestone in BIOTRONIK’s goal to deliver our innovative peripheral intervention products to US physicians,” explained Dr. Daniel Bühler, President Vascular Intervention, BIOTRONIK. “We look forward to positive results from this portion of BIOFLEX-I, and feel sure that we will ultimately be able to provide physicians with further proven treatment options for cardiovascular disease.”

More information on the BIOFLEX-I clinical study is available at www.clinicaltrials.gov identifier: NCT01319812.

Related Content

Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access
FDA clears AI screening tool for cardiac amyloidosis
IVUS-guided PCI reduces risks in patients with diabetes
SCCT leaders unpack the 2025 Medicare payment increase for coronary CTA
Global shortage of nuclear imaging isotopes may be over
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."